Equities

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Actions
  • Price (EUR)54.00
  • Today's Change1.50 / 2.86%
  • Shares traded0.00
  • 1 Year change+100.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments559334334
Total Receivables, Net9.102.291.48
Total Inventory------
Prepaid expenses6.508.479.54
Other current assets, total------
Total current assets574345345
Property, plant & equipment, net574.994.72
Goodwill, net------
Intangibles, net------
Long term investments0.4701.01
Note receivable - long term------
Other long term assets2.000.710.07
Total assets635352351
LIABILITIES
Accounts payable6.556.88--
Accrued expenses35197.53
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total2.062.24--
Total current liabilities442816
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total528.133.08
Total liabilities963619
SHAREHOLDERS EQUITY
Common stock1,192759608
Additional paid-in capital------
Retained earnings (accumulated deficit)(654)(439)(275)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.98(3.93)(0.38)
Total equity539316332
Total liabilities & shareholders' equity635352351
Total common shares outstanding685448
Treasury shares - common primary issue000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.